Legal & transparency
Editorial Standards & Transparency
We aim to help visitors distinguish verified evidence from uncertainty, without promoting a particular medicine.
Source hierarchy
We prioritize current regulatory documents, FDA prescribing information, published clinical research, government insurance datasets, and source-linked manufacturer price terms.
Evidence context
Where available, we show trial dosage, duration, population and source. Results from different studies should not be interpreted as head-to-head comparisons.
Review and uncertainty
Information is reviewed before being represented as verified. Missing data is labeled as unverified or unavailable rather than guessed. Source dates and ongoing changes matter.
Corrections
We welcome factual corrections and broken-link reports through our contact channel. Review and update frequency depends on source availability; we do not promise real-time coverage.
Commercial independence
MyDosePro does not currently present itself as a pharmacy or prescriber. If advertising, affiliate relationships or paid partnerships are introduced, material connections must be disclosed clearly alongside relevant content.
Effective October 12, 2026. This general information requires independent legal review, particularly for EU and US consumer requirements.